James E. D. Thaventhiran

Researcher, MRC Toxicology Unit, University of Cambridge
The adaptive immune system depends on the vast proliferation of anti-pathogen lymphocytes. In order to proliferate in this way, lymphocytes have to maintain their replicative capacity in the face of anti-proliferative signals delivered by inflammation. My prior work has studied how the signal for terminal differentiation in these cells could be linked to the magnitude of their proliferation.

My current focus is the study of how responding adaptive immune lymphocytes avoid the anti-proliferative signals of inflammation. This work has received substantial support from the MRC and hopes to identify new pathways for the therapeutic manipulation of immune responses. These scientific objectives stem directly from my clinical work, based at Addenbrooke’s hospital, where I look after patients with primary and secondary immunodeficiency. An ongoing research priority within our clinical department is the identification of novel immunodeficiencies and therapies.

More from this expert